In this video, Lindsay T. Fourman, MD, talks about the hepatic and metabolic characteristics of patients with HIV and nonalcoholic fatty liver disease.
Additional Resources:
- Fourman LT, Stanley TL, Feldpausch M, et al. Clinical predictors of liver fibrosis presence and progression in HIV-associated NAFLD. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020. Boston, Massachusetts. http://www.croiconference.org/sessions/clinical-predictors-liver-fibrosis-presence-progression-hiv-associated-nafld.
- Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD
- Effects of Tesamorelin on Liver Fat and Histology in HIV+NAFLD
- How NAFLD Affects Patients With HIV Differently Than the General Public
- Take-Away Messages About Liver Fibrosis in Patients With HIV+NAFLD
Lindsay T. Fourman, MD, is a physician at Massachusetts General Hospital in Boston, Massachusetts.
TRANSCRIPT:
Lindsay T. Fourman: In our study, our patient population was in their 50s, had well‑controlled HIV infection that tended to be chronic with a duration of about 15 years. Patients were, as I said, well controlled, virologically suppressed, and on modern antiretroviral therapies, with about 60% of them on integrase inhibitors. This really speaks to the generalizability of our findings.
We saw that the BMI in our sample was about 30 on average, 30 kg/m2. That's interesting because it also shows that not everyone was obese to have NAFLD in our study and roughly half were not obese.
That really speaks to the heterogeneity of body composition in people with HIV and some patients having a disproportionate accumulation of visceral fat even if they're not obese and the presence of lipodystrophy at the extreme of that.
We also saw in our sample that the amount of hepatic fat was about 14%, and the prevalence of NASH in our sample, or nonalcoholic steatohepatitis, was about 30% in our sample. A fairly affected sample with pretty pronounced hepatic disease.
